Median duration of treatment was 23 months for dasatinib (with 44% of patients treated for > 24 months to date) and 3 months for imatinib (with 10% of patients treated for > 24 months to date).
Hoidon keston mediaani dasatinibilla oli 23 kuukautta (44%: a potilaista hoidettiin > 24 kuukautta) ja imatinibilla 3 kuukautta (10%: a potilaista > 24 kuukautta).